Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

This study is testing whether cisplatin (a standard platinum-based chemotherapy) is effective in patients with advanced pancreatic cancer whose tumors have a specific DNA repair defect called homologous recombination deficiency (HRD). This defect makes cancer cells more vulnerable to certain chemotherapies, and the researchers want to see if cisplatin can exploit this weakness. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with advanced pancreatic adenocarcinoma (confirmed by biopsy or tissue analysis) - Your cancer has progressed despite at least one prior chemotherapy regimen - Genetic or molecular testing has confirmed your tumor has homologous recombination deficiency - You are in reasonably good health (ECOG 0-2) - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have severe kidney, liver, or heart problems - Your cancer has spread to the brain - You have had cisplatin or other platinum chemotherapy recently Talk to your doctor to see if this trial is right for you.